CA3023787A1 - Anti-ctla-4 antibodies - Google Patents

Anti-ctla-4 antibodies Download PDF

Info

Publication number
CA3023787A1
CA3023787A1 CA3023787A CA3023787A CA3023787A1 CA 3023787 A1 CA3023787 A1 CA 3023787A1 CA 3023787 A CA3023787 A CA 3023787A CA 3023787 A CA3023787 A CA 3023787A CA 3023787 A1 CA3023787 A1 CA 3023787A1
Authority
CA
Canada
Prior art keywords
antibody
cell
binding fragment
antigen binding
ctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3023787A
Other languages
English (en)
French (fr)
Inventor
Cheng-I Wang
Eve Ngoh
Siok Ping YEO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of CA3023787A1 publication Critical patent/CA3023787A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
CA3023787A 2016-05-10 2017-04-13 Anti-ctla-4 antibodies Abandoned CA3023787A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201603721TA SG10201603721TA (en) 2016-05-10 2016-05-10 Anti-CTLA-4 Antibodies
SG10201603721T 2016-05-10
PCT/EP2017/058956 WO2017194265A1 (en) 2016-05-10 2017-04-13 Anti-CTLA-4 Antibodies

Publications (1)

Publication Number Publication Date
CA3023787A1 true CA3023787A1 (en) 2017-11-16

Family

ID=58609383

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3023787A Abandoned CA3023787A1 (en) 2016-05-10 2017-04-13 Anti-ctla-4 antibodies

Country Status (10)

Country Link
US (2) US9758583B2 (https=)
EP (1) EP3455255B1 (https=)
JP (1) JP6650537B2 (https=)
KR (1) KR20190015715A (https=)
CN (1) CN109563165B (https=)
AU (1) AU2017262448A1 (https=)
CA (1) CA3023787A1 (https=)
SG (2) SG10201603721TA (https=)
TW (1) TW201739763A (https=)
WO (1) WO2017194265A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356163B (es) 2011-12-01 2018-05-16 Chemocentryx Inc Anilinas sustituidas como antagonistas de ccr(4).
CN107667173A (zh) 2015-05-06 2018-02-06 斯尼普技术有限公司 改变微生物种群和改善微生物群
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
CA3073984A1 (en) 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4 antibodies and uses thereof
CN111954680B (zh) 2017-11-10 2024-03-15 新加坡科技研究局 IL2Rβ/共同γ链抗体
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US20210038646A1 (en) * 2018-02-12 2021-02-11 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CA3100349A1 (en) * 2018-05-17 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
CN112601526B (zh) 2018-08-29 2025-10-03 凯莫森特里克斯股份有限公司 使用c-c趋化因子受体4(ccr4)拮抗剂和一种或多种检查点抑制剂的联合治疗
TW202031683A (zh) 2018-11-09 2020-09-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
TW202039557A (zh) 2018-11-09 2020-11-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
AU2019413366B2 (en) * 2018-12-27 2025-06-05 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN110343180B (zh) * 2019-07-25 2021-03-30 北京免疫方舟医药科技有限公司 抗ctla-4抗体及其应用
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
CN116249715A (zh) * 2020-06-11 2023-06-09 南特生物科学公司 抗ctla4单克隆抗体和嵌合抗原受体
CA3184082A1 (en) * 2020-07-02 2022-01-06 David Scott Johnson Anti-ctla-4 binding proteins and methods of use thereof
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022169269A1 (ko) * 2021-02-03 2022-08-11 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
RU2757418C1 (ru) * 2021-03-04 2021-10-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный университет" Тетрадекапептидный антагонист взаимодействия CTLA-4 c B7-1
AU2022253351A1 (en) 2021-04-09 2023-10-12 Boehringer Ingelheim International Gmbh New scaffold for bifunctional molecules with improved properties
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
AU2024254671A1 (en) 2023-03-30 2025-10-02 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
CN121358499A (zh) 2023-03-30 2026-01-16 Ose免疫疗法 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途
WO2025137321A1 (en) * 2023-12-21 2025-06-26 Fenwal, Inc. System and method for affinity cell selection
EP4599843A1 (en) 2024-02-09 2025-08-13 Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau Car and modified cd200r combination
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
ITRM20010408A1 (it) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
EP1471938A4 (en) 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
EP2287195B1 (en) 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
EP2054444B1 (en) 2006-08-04 2016-11-02 MedImmune Limited Antibodies to erbb2
US7994306B2 (en) 2006-11-13 2011-08-09 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of treating cancer using siRNA molecules directed against CD24
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
EA201000910A1 (ru) 2007-11-30 2011-04-29 Бристоль-Мейерз Сквибб Компани Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
US9249225B2 (en) 2010-05-26 2016-02-02 Regents Of The University Of Minnesota Single chain variable fragment anti-CD133 antibodies and uses thereof
SMT201700185T1 (it) 2010-08-23 2017-05-08 Univ Texas Anticorpi anti-ox40 e metodi di uso degli stessi
SMT201800269T1 (it) 2011-04-25 2018-07-17 Daiichi Sankyo Co Ltd Anticorpo anti-b7-h3
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
HK1200468A1 (en) 2011-09-30 2015-08-07 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
SG11201601763SA (en) 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies

Also Published As

Publication number Publication date
SG11201809857TA (en) 2018-12-28
AU2017262448A1 (en) 2019-01-03
US20170226211A1 (en) 2017-08-10
KR20190015715A (ko) 2019-02-14
US11267887B2 (en) 2022-03-08
US9758583B2 (en) 2017-09-12
US20190153097A1 (en) 2019-05-23
CN109563165A (zh) 2019-04-02
JP6650537B2 (ja) 2020-02-19
JP2019519208A (ja) 2019-07-11
EP3455255B1 (en) 2021-03-03
EP3455255A1 (en) 2019-03-20
WO2017194265A1 (en) 2017-11-16
CN109563165B (zh) 2020-09-25
SG10201603721TA (en) 2017-12-28
TW201739763A (zh) 2017-11-16

Similar Documents

Publication Publication Date Title
US12472252B2 (en) Anti-PD-L1 antibodies
US9758583B2 (en) Anti-CTLA-4 antibodies
US11142574B2 (en) Anti-TIM-3 antibodies
US20190040136A1 (en) Anti-lag-3 antibodies
CA2965623A1 (en) Anti-pd-1 antibodies
CA2965627A1 (en) Anti-tim-3 antibodies
HK40000388A (en) Anti-ctla-4 antibodies
HK1246324B (en) Anti-pd-l1 antibodies

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221013